Patients report high satisfaction with PureSee IOL

WASHINGTON — Patients who received the Tecnis PureSee extended depth of focus IOL had a high tolerance to residual refractive error, according to a study.
At the American Society of Cataract and Refractive Surgery meeting, Vance Thompson, MD, presented data from a prospective, bilateral implant study that compared the Tecnis PureSee IOL extended depth of focus (EDOF) IOL (Johnson & Johnson, 113 patients) with a monofocal control IOL (Tecnis model DCB00, Johnson & Johnson, 110 patients). Key study endpoints at 6 months included binocular defocus curve visual acuity, absolute spherical

KPro can help patients maintain vision after failed keratoplasty

WASHINGTON — Patients with bilateral limbal cell deficiency or previous failed keratoplasty may be candidates for KPro, according to a speaker.
In a presentation at Cornea Day at the American Society of Cataract and Refractive Surgery meeting, Soledad Cortina, MD, of the University of Illinois Eye and Ear Infirmary, said corneal transplantations have had a lot of success, and the risk associated with the first graft is generally low. However, not all patients are candidates for keratoplasty, she said, and there are situations in which she will instead turn to KPro (CorNeat).
“Essentially, the

New study shows linens, not equipment emissions, dominate ultrasound’s carbon footprint

A new research study published in the Journal of the American College of Radiology (JACR) has found that unlike other modalities, linens and disposable supplies account for the vast majority of ultrasound's annual carbon emissions—not equipment energy use. The study, titled "Harmonizing Diagnostic Ultrasound Practice with Environmental Sustainability: A Life Cycle Assessment of Diagnostic Ultrasound in a Single Adult University Hospital," determined that linens (35%) and other single-use supplies (34%) accounted for most of ultrasound's greenhouse gas emissions, whereas production (7%) and energy use (3%) of the ultrasound equipment were minor contributors.

As RSV evolves, a two‑pronged antibody cocktail aims to stay ahead

Scientists in China have developed a two-antibody cocktail to treat respiratory syncytial virus, or RSV, that in laboratory studies prevented the virus from developing drug resistance—a persistent problem with current therapies for infants. RSV is a seasonal infection that circulates globally and can be especially dangerous for people at opposite ends of the age spectrum: infants and older adults. Vaccines are available for those who are 65 and older (GlaxoSmithKline's Arexvy, Pfizer's ABRYSVO and Moderna's mRESVIA), but there is still no available vaccine for infants who are among the most vulnerable.

Immune cells in the nose slow influenza virus, study finds

A new study from the University of Gothenburg may help guide the development of better influenza vaccines. Memory cells in the nose slow the influenza virus as soon as it enters the body. They reduce viral levels and may help protect against more severe illness. The findings are published in the Journal of Experimental Medicine.